Comprison of the renoprotecrive and the antihypertensive effects of Olmesartan vs Losartan + low dose diuretics in normoalbuminuric diabetic patients

Comprison of the renoprotecrive and the antihypertensive effects of Olmesartan vs Losartan + low dose diuretics in normoalbuminuric diabetic patients - Evaluation of renoprotective effects of Olmesartan in normoalbuminuric diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000729

Enrollment

Registered

2007-06-10

Start date

2007-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Olmesartan (20mg) Losartan (50mg) + hydrochlorothiazide (12.5mg) or trichlorothiazide (1mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. BP > 130 / 80 mmHg by losartan 50mg, telmisartan 20mg, valsartan 80mg or candesartan 8mg 2. All three consecutive spot urinary albumin measurements at outpatients' clinic within 1 year < 30mg /gCr

Exclusion criteria

Exclusion criteria: 1. Past history of microalbuminuria, overt proteinuria or any kidney diseases 2. Pregnancy 3. Severe liver dysfunction 4. Cancer 5. Poor glycemic control (HbA1c > 10%) 6. Other reasons for exclusion

Design outcomes

Primary

Measure	Time frame
1. changes in urinary IgG, transferrin and ceruloplasmin excretions 2. blood pressure lowering effects.	—

Countries

Japan

Contacts

Public ContactTakuma Narita

Akita University School of Medicine Endocrinology, diabetes and geriatric medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026